View ValuationTetratherix 향후 성장Future 기준 점검 2/6Tetratherix (는) 각각 연간 17% 및 50.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 22.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -28.7% 로 예상됩니다.핵심 정보17.0%이익 성장률22.80%EPS 성장률Biotechs 이익 성장39.4%매출 성장률50.8%향후 자기자본이익률-28.74%애널리스트 커버리지Low마지막 업데이트12 Jun 2026최근 향후 성장 업데이트Major Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.Major Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.모든 업데이트 보기Recent updatesMajor Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.공시 • May 29Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million.Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 333,333 Price\Range: AUD 6공시 • May 28Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 6 Discount Per Security: AUD 0.36 Transaction Features: Subsequent Direct ListingMajor Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.Reported Earnings • Feb 27First half 2026 earnings released: AU$0.092 loss per share (vs AU$0.086 loss in 1H 2025)First half 2026 results: AU$0.092 loss per share (further deteriorated from AU$0.086 loss in 1H 2025). Net loss: AU$4.62m (loss widened 122% from 1H 2025). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Biotechs industry in Australia.New Risk • Jan 28New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Revenue is less than US$1m (AU$1.1m revenue, or US$737k). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (AU$8.9m net loss in 3 years).공시 • Jan 21Tetratherix Limited Confirms Appointment of Maurizio Vecchione as Independent Non-Executive DirectorTetratherix Limited has confirmed the appointment of Mr. Maurizio Vecchione as an independent non-executive director. Mr. Vecchione has obtained the required director identification number from the Australian Business Registry Services and has provided a consent to act as a director to the Tetratherix Board. Mr. Vecchione is the Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation and General Partner at AdAstral Funds. He is also named on multiple patents filed in the United States related to material and nano-bio-polymers. Mr. Vecchione has spent the last 30 years at the forefront of biomedicine. He has helped build nine startups and launch more than 50 commercial products spanning health technologies and material sciences. His prior experience includes being Chief Executive Officer at Arrogene Nanotechnology, CompuMED, Trestle and multiple other science companies.Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Peter Gray was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 10Tetratherix Limited, Annual General Meeting, Nov 10, 2025Tetratherix Limited, Annual General Meeting, Nov 10, 2025. Location: automic group, level 5, 126 phillip street sydney, nsw 2000, AustraliaReported Earnings • Sep 02Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: AU$0.36 loss per share (further deteriorated from AU$0.11 loss in FY 2024). Net loss: AU$9.43m (loss widened 269% from FY 2024). Revenue exceeded analyst estimates by 186%. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Biotechs industry in Australia.New Risk • Jul 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$507k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).New Risk • Jul 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$502k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).New Risk • Jul 07New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$8.4m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$8.4m). Revenue is less than US$1m (AU$777k revenue, or US$505k).공시 • Jun 27Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million.Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,680,000 Price\Range: AUD 2.88 Discount Per Security: AUD 0.1728이익 및 매출 성장 예측ASX:TTX - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202817-5-2-536/30/20278-6-6-736/30/20266-6-5-8312/31/20252-12-9-7N/A9/30/20252-11-6-5N/A6/30/20251-9-3-3N/A3/31/20251-6-3-2N/A12/31/20241-3-2-2N/A9/30/20241-3-2-2N/A6/30/20241-3-3-3N/A6/30/20231-200N/A6/30/20221-2-1-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: TTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: TTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: TTX 의 수익(연간 50.8%)이 Australian 시장(연간 6.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: TTX 의 수익(연간 50.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TTX는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/20 13:45종가2026/06/19 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tetratherix Limited는 2명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Melissa BensonBarrenjoey Markets Pty LimitedScott PowerMorgans Financial Limited
Major Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.
Major Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.
Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.
Major Estimate Revision • Jun 12Consensus EPS estimates upgraded to AU$0.082 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.149 to -AU$0.082 per share. Revenue forecast unchanged from AU$5.87m at last update. Biotechs industry in Australia expected to see average net income decline 0.4% next year. Consensus price target broadly unchanged at AU$6.05. Share price was steady at AU$6.00 over the past week.
공시 • May 29Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million.Tetratherix Limited has filed a Follow-on Equity Offering in the amount of AUD 1.999998 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 333,333 Price\Range: AUD 6
공시 • May 28Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million.Tetratherix Limited has completed a Follow-on Equity Offering in the amount of AUD 15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 2,500,000 Price\Range: AUD 6 Discount Per Security: AUD 0.36 Transaction Features: Subsequent Direct Listing
Major Estimate Revision • Apr 24Consensus revenue estimates increase by 58%, EPS downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$3.65m to AU$5.77m. EPS estimate fell from -AU$0.193 to -AU$0.216 per share. Biotechs industry in Australia expected to see average net income growth of 2.8% next year. Consensus price target up from AU$5.52 to AU$5.72. Share price fell 3.9% to AU$4.73 over the past week.
Major Estimate Revision • Mar 17Consensus revenue estimates increase by 135%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from AU$1.55m to AU$3.65m. EPS estimate unchanged from -AU$0.19 at last update. Biotechs industry in Australia expected to see average net income growth of 7.9% next year. Consensus price target up from AU$4.88 to AU$5.52. Share price rose 40% to AU$5.60 over the past week.
Reported Earnings • Feb 27First half 2026 earnings released: AU$0.092 loss per share (vs AU$0.086 loss in 1H 2025)First half 2026 results: AU$0.092 loss per share (further deteriorated from AU$0.086 loss in 1H 2025). Net loss: AU$4.62m (loss widened 122% from 1H 2025). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Biotechs industry in Australia.
New Risk • Jan 28New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Revenue is less than US$1m (AU$1.1m revenue, or US$737k). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (AU$8.9m net loss in 3 years).
공시 • Jan 21Tetratherix Limited Confirms Appointment of Maurizio Vecchione as Independent Non-Executive DirectorTetratherix Limited has confirmed the appointment of Mr. Maurizio Vecchione as an independent non-executive director. Mr. Vecchione has obtained the required director identification number from the Australian Business Registry Services and has provided a consent to act as a director to the Tetratherix Board. Mr. Vecchione is the Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation and General Partner at AdAstral Funds. He is also named on multiple patents filed in the United States related to material and nano-bio-polymers. Mr. Vecchione has spent the last 30 years at the forefront of biomedicine. He has helped build nine startups and launch more than 50 commercial products spanning health technologies and material sciences. His prior experience includes being Chief Executive Officer at Arrogene Nanotechnology, CompuMED, Trestle and multiple other science companies.
Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Peter Gray was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 10Tetratherix Limited, Annual General Meeting, Nov 10, 2025Tetratherix Limited, Annual General Meeting, Nov 10, 2025. Location: automic group, level 5, 126 phillip street sydney, nsw 2000, Australia
Reported Earnings • Sep 02Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: AU$0.36 loss per share (further deteriorated from AU$0.11 loss in FY 2024). Net loss: AU$9.43m (loss widened 269% from FY 2024). Revenue exceeded analyst estimates by 186%. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Biotechs industry in Australia.
New Risk • Jul 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$507k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).
New Risk • Jul 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$4.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Shares are highly illiquid. Negative equity (-AU$8.4m). Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m (AU$777k revenue, or US$502k). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$10m net loss in 2 years).
New Risk • Jul 07New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AU$8.4m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-AU$8.4m). Revenue is less than US$1m (AU$777k revenue, or US$505k).
공시 • Jun 27Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million.Tetratherix Limited has completed an IPO in the amount of AUD 24.9984 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,680,000 Price\Range: AUD 2.88 Discount Per Security: AUD 0.1728